Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.03−0.03 (-2.83%)
Close on Nov 18, 2026Market cap $103.35MP/E –Yield –
Cellectis shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Cellectis's shares outstanding was 101M at Jun 30, 2026. For fiscal 2025 it was 100M, up 10.7% from the year before. Over ten years it grew 11.4% a year on average. The highest annual figure on record is 100M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 100M | +10.7% |
| FY2024 | Dec 31, 2024 | 91M | +58.9% |
| FY2023 | Dec 31, 2023 | 57M | +25.2% |
| FY2022 | Dec 31, 2022 | 46M | +1.6% |
| FY2021 | Dec 31, 2021 | 45M | +5.5% |
| FY2020 | Dec 31, 2020 | 43M | +0.1% |
| FY2019 | Dec 31, 2019 | 42M | +4.1% |
| FY2018 | Dec 31, 2018 | 41M | +14.2% |
| FY2017 | Dec 31, 2017 | 36M | +1.2% |
| FY2016 | Dec 31, 2016 | 35M | +3.3% |
| FY2015 | Dec 31, 2015 | 34M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 101M | +121.2% |
| Q2 FY2025 | Jun 30, 2025 | 100M | +120.6% |
| Q2 FY2024 | Jun 30, 2024 | 90M | +111.6% |
| Q2 FY2023 | Jun 30, 2023 | 56M | +31.0% |
| Q2 FY2022 | Jun 30, 2022 | 46M | – |
| Q2 FY2021 | Jun 30, 2021 | 45M | – |
| Q2 FY2020 | Jun 30, 2020 | 42M | – |
| Q2 FY2019 | Jun 30, 2019 | 42M | – |
See a number that looks wrong?